Pharmacogenetic heterogeneity of transgene expression in muscle and tumours

BMC Pharmacology

Volumn 3, Issue , 2003, Pages

  Lefesvre, Pierre ^a   Attema, Joline ^a   van Bekkum, Dirk ^a  

^a CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; VIRUS DNA;

ADENOVIRUS; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENE TARGETING; GENETIC CODE; GENETIC HETEROGENEITY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INBRED STRAIN; MALE; MOLECULAR DYNAMICS; MUSCLE TISSUE; NONHUMAN; PHARMACOGENETICS; PHENOTYPE; RAT; STRAIN DIFFERENCE; TRANSGENE; TUMOR CELL LINE; VIRUS VIRULENCE; ANIMAL; BAGG ALBINO MOUSE; BROWN NORWAY RAT; C57BL MOUSE; FISCHER 344 RAT; GENE VECTOR; GENETICS; METABOLISM; METHODOLOGY; MOUSE; NEOPLASM; PATHOLOGY; RAT STRAIN; SKELETAL MUSCLE; SPECIES DIFFERENCE; STANDARD;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION; GENETIC VECTORS; HUMANS; LUCIFERASES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MUSCLE, SKELETAL; NEOPLASMS; RATS; RATS, INBRED BN; RATS, INBRED F344; RATS, INBRED STRAINS; SPECIES SPECIFICITY; TRANSFECTION; TRANSGENES;

EID: 0642275755     PISSN: 14712210     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2210-3-11     Document Type: Article

References (41)

1. Sterman DH, Kaiser LR and Albelda SM: Gene therapy for malignant pleural mesothelioma. Hematol Oncol Clin North Am 1998, 12:553-568.
2. Swisher SG and Roth JA: p53 Gene therapy for lung cancer. Curr Oncol Rep 2002, 4:334-340.
3. Molnar-Kimber KL, Sterman DH, Chang M, Kang EH, ElBash M, Lanuti M, Elshami A, Gelfand K, Wilson JM, Kaiser LR and Albelda SM: Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998, 9:2121-2133.
4. Blackwell JL, Li H, Gomez-Navarro J, Dmitriev I, Krasnykh V, Richter CA, Shaw DR, Alvarez RD, Curiel DT and Strong TV: Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid. Hum Gene Ther 2000, 11:1657-1669.
5. Joseph PM, O'Sullivan BP, Lapey A, Dorkin H, Oren J, Balfour R, Perricone MA, Rosenberg M, Wadsworth SC, Smith AE, St George JA and Meeker DP: Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. Hum Gene Ther 2001, 12:1369-1382.
6. Piedra PA, Poveda GA, Ramsey B, McCoy K and Hiatt PW: Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. Pediatrics 1998, 101:1013-1019.
7. Fox JP, Hall CE and Cooney MK: The Seattle Virus Watch. VII. Observations of adenovirus infections. Am J Epidemiol 1977, 105:362-386.
8. Havenga MJ, Lemckert AA, Ophorst OJ, van Meijer M, Germeraad WT, Grimbergen J, van Den Doel MA, Vogels R, van Deutekom J, Janson AA, de Bruijn JD, Uytdehaag F, Quax PH, Logtenberg T, Mehtali M and Bout A: Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol 2002, 76:4612-4620.
9. Tao N, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM, Barsoum J and Fawell SE: Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 2001, 3:28-35.
10. Mazzolini G, Narvaiza I, Perez-Diez A, Rodriguez-Calvillo M, Qian C, Sangro B, Ruiz J, Prieto J and Melero I: Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12. Gene Ther 2001, 8:259-267.
11. Wen XY, Bai Y and Stewart AK: Adenovirus-mediated human endostatin gene delivery demonstrates strain- specific antitumor activity and acute dose-dependent toxicity in mice. Hum Gene Ther 2001, 12:347-358.
12. Barr D, Tubb J, Ferguson D, Scaria A, Lieber A, Wilson C, Perkins J and Kay MA: Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther 1995, 2:151-155.
13. Peng Y, Falck-Pedersen E and Elkon KB: Variation in adenovirus transgene expression between BALB/c and C57BL/6 mice is associated with differences in interleukin-12 and gamma interferon production and NK cell activation. J Virol 2001, 75:4540-4550.
14. Lefesvre P, Attema J and Van Bekkum D: Genetic heterogeneity in response to adenovirus gene therapy. Submitted to BMC Mol Biol.
15. Ishii A, Hagiwara Y, Saito Y, Yamamoto K, Yuasa K, Sato Y, Arahata K, Shoji S, Nonaka I, Saito I, Nabeshima Y and Takeda S: Effective adenovirus-mediated gene expression in adult murine skeletal muscle. Muscle Nerve 1999, 22:592-599.
16. Loser P, Hillgenberg M, Arnold W, Both GW and Hofmann C: Ovine adenovirus vectors mediate efficient gene transfer to skeletal muscle. Gene Ther 2000, 7:1491-1498.
17. Nakada K, Nakada F, Ito E and Inoue F: Quantification of myonecrosis and comparison of necrotic activity of snake venoms by determination of creatine phosphokinase activity in mice sera. Toxicon 1984, 22:921-930.
18. Steiness E, Rasmussen F, Svendsen O and Nielsen P: A comparative study of serum creatine phosphokinase (CPK) activity in rabbits, pigs and humans after intramuscular injection of local damaging drugs. Acta Pharmacol Toxicol (Copenh) 1978, 42:357-364.
19. Ginn SL, Fleming J, Rowe PB and Alexander IE: Promoter Interference Mediated by the U3 Region in Early-Generation HIV-1-Derived Lentivirus Vectors Can Influence Detection of Transgene Expression in a Cell-Type and Species-Specific Manner. Hum Gene Ther 2003, 14:1127-1137.
20. Vlachaki MT, Hernandez-Garcia A, Ittmann M, Chhikara M, Aguilar LK, Zhu X, The BS, Butler EB, Woo S, Thompson TC, Barrera-Saldana H and Aguilar-Cordova E: Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol Ther 2002, 6:342-348.
21. Bramson JL, Hitt M, Gauldie J and Graham FL: Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther 1997, 4:1069-1076.
22. Kal HB, Zurcher C and van Bekkum DW: Induction of lung tumors by radioactive isotopes implanted in the rat lung. J Natl Cancer Inst 1986, 76:943-946.
23. Marquet RL, Westbroek DL and Jeekel J: Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site. Int J Cancer 1984, 33:689-692.
24. Kal HB, Meijnders PJ, Van Berkel AH and Van Bekkum DW: Response to chemotherapy of non-small cell bronchial rat tumours growing subcutaneously or in the lung. In Vivo 1991, 5:301-306.
25. Craighead JE, Akley NJ, Gould LB and Libbus BL: Characteristics of tumors and tumor cells cultured from experimental asbestos-induced mesotheliomas in rats. Am J Pathol 1987, 129:448-462.
26. Minna JD, Bunn P. A., Jr., Carney DN, Cohen MH, Cuttita F, Fosieck B. E., Jr., Gazdar AF, Ihde DC, Johnston-Early A, Matthews MJ, Makuch R, Oie H, Rosen S, Lichter A and Glatstein E: Experience of the National Cancer Institute (USA) in the treatment and biology of small cell lung cancer. Bull Cancer 1982, 69:83-93.
27. Lieber M, Smith B, Szakal A, Nelson-Rees W and Todaro G: A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int J Cancer 1976, 17:62-70.
28. Tom BH, Rutzky LP, Jakstys MM, Oyasu R, Kaye CI and Kahan BD: Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro 1976, 12:180-191.
29. Engel LW and Young NA: Human breast carcinoma cells in continuous culture: a review. Cancer Res 1978, 38:4327-4339.
30. Cailleau R, Young R, Olive M and Reeves W. J., Jr.: Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 1974, 53:661-674.
31. Brinkley BR, Beall PT, Wible LJ, Mace ML, Turner DS and Cailleau RM: Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res 1980, 40:3118-3129.
32. Trempe GL: Human breast cancer in culture. Recent Results Cancer Res 1976:33-41.
33. Soule HD, Vazguez J, Long A, Albert S and Brennan M: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973, 51:1409-1416.
34. Havenga MJ, Lemckert AA, Grimbergen JM, Vogels R, Huisman LG, Valerio D, Bout A and Quax PH: Improved adenovirus vectors for infection of cardiovascular tissues. J Virol 2001, 75:3335-3342.
35. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D and Hoeben RC: New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998, 9:1909-1917.
36. Lamfers ML, Lardenoye JH, de Vries MR, Aalders MC, Engelse MA, Grimbergen JM, van Hinsbergh VW and Quax PH: In vivo suppression of restenosis in balloon-injured rat carotid artery by adenovirus-mediated gene transfer of the cell surface-directed plasmin inhibitor ATF.BPTI. Gene Ther 2001, 8:534-541.
37. Fallaux FJ, Kranenburg O, Cramer SJ, Houweling A, Van Ormondt H, Hoeben RC and Van Der Eb AJ: Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996, 7:215-222.
38. Shabram PW, Giroux DD, Goudreau AM, Gregory RJ, Horn MT, Huyghe BG, Liu X, Nunnally MH, Sugarman BJ and Sutjipto S: Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum Gene Ther 1997, 8:453-465.
39. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
40. Klein D, Bugl B, Gunzburg WH and Salmons B: Accurate estimation of transduction efficiency necessitates a multiplex realtime PCR. Gene Ther 2000, 7:458-463.
41. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159.